P
Pear Therapeutics Inc
NASDAQ:PEAR
Pear Therapeutics Inc
NASDAQ:PEAR
Price:
0.0077 USD
-15.38%
Updated:
May 7, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of PEAR.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PEAR
Relative Value
Base Case
Not Available
P
Valuation Multiples
Multiples Across Competitors
PEAR Competitors Multiples
Pear Therapeutics Inc Competitors
Pear Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
P
|
Pear Therapeutics Inc
NASDAQ:PEAR
|
1.1m USD | 0.1 | -0 | 0.5 | 0.5 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
32.9B USD | 13.9 | 62.5 | 62.6 | 67.3 | |
| US |
|
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 4.8 | 47.3 | 19.6 | 38.6 | |
| US |
|
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | 2.6 | -116.8 | 16.5 | 111.6 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
11.8B AUD | 80.8 | 169.5 | 116.5 | 116.5 | |
| US |
|
Inspire Medical Systems Inc
NYSE:INSP
|
7.4B USD | 11.9 | -350.7 | -185.9 | -172.8 | |
| JP |
|
M3 Inc
TSE:2413
|
1.2T JPY | 4.9 | 24.9 | 13 | 14.6 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 9.7 | 33 | 22.1 | 23.5 | |
| SE |
|
Sectra AB
STO:SECT B
|
42.6B SEK | 26.3 | 101.3 | -66.1 | -66.1 | |
| US |
|
Evolent Health Inc
NYSE:EVH
|
3.1B USD | 1.6 | -21.8 | 25.7 | 274 | |
| US |
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
3B USD | 4 | -339.5 | 35.9 | -117.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
